UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, with revenue of 4.178 billion euros in 2016. The company focuses primarily on research and development, specifically medications for epilepsy, Parkinson's disease and Crohn's disease, and its efforts concentrate on treatments for severe diseases treated by specialists in central nervous system disorders, inflammatory disorders and oncology.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.